Over time, medical companies such as Pfizer and Moderna, Inc. (NASDAQ:MRNA), a biotechnology company based in Cambridge ... and consumer health products. Johnson and Johnson (NYSE:JNJ)’s ...

Johnson & Johnson is replacing its instantly recognizable logo that’s been in use for 135 years. Gone is the cursive, which was based off the handwritten signature of company co-founder James ...

At today’s meeting, members of Johnson & Johnson’s Executive Committee and leaders from the Innovative Medicine and MedTech businesses will highlight the Company’s key drivers for sustained ...

Prior to today's trading, shares of the world's biggest maker of health care products ... the performance of Johnson & Johnson in its upcoming earnings disclosure. The company's earnings report ...

Johnson & Johnson (JNJ) reported $25.53 billion in revenue for the quarter ended June 2023, representing a year-over-year increase of 6.3%. EPS of $2.80 for the same period compares to $2.59 a ...

Consumer health company Kenvue separated from Johnson & Johnson in May. J&J and Kenvue both reported better-than-expected results for the second quarter on resilient demand for their products.

Dec 5 (Reuters) - Johnson ... adding the company's profit per share target is "always very conservative." Sales of Stelara in Europe are expected to come under pressure as a key patent on ...

The filing is not an admission of wrongdoing and the company maintains its position that the talcum powder products are safe, according to the release. Johnson & Johnson and its other affiliates ...

In this article, we are going to take a look at where Johnson & Johnson (NYSE ... with a steady demand for products and services due to the biological nature of humans. Stocks like Pfizer Inc ...